Harmony Biosciences
$35.59
45
+$0.03+0.08% Friday 20:00
统计数据
当日最高
35.99
当日最低
35.2
52周最高
39.27
52周最低
18.61
成交量
267,948
平均成交量
368,172
市值
2.04B
市盈率
18.45
股息收益率
-
股息
-
即将到来
收益
29Oct预期
预期每股收益
0.663333
实际每股收益
N/A
人们还关注
此列表基于关注HRMY的Stock Events用户的观察列表。这不是投资建议。
竞争者
这个列表是基于最近市场事件的分析。这不是投资建议。
Jazz Pharmaceuticals
JAZZ
市值7.16B
Avadel Pharmaceuticals
AVDL
市值1.46B
Axsome Therapeutics
AXSM
市值4.27B
Teva- Pharmaceutical Industries
TEVA
市值21.38B
Biogen
BIIB
市值29.83B
Sage Therapeutics
SAGE
市值514.65M
Supernus Pharmaceuticals
SUPN
市值1.94B
Palatin Technologies
PTN
市值31.57M
分析师评级
49.67$平均价格目标
最高估值为 $52。
来自过去6个月内的 3 个评级。这不是投资建议。
买入
100%
持有
0%
卖出
0%
关于
Health Technology
Pharmaceuticals: Major
Manufacturing
Medicinal and Botanical Manufacturing
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Show more...
首席执行官
员工
246
国家
US
ISIN
US4131971040